

David M Asmuth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7620207/publications.pdf>

Version: 2024-02-01

71
papers

3,249
citations

172457
29
h-index

149698
56
g-index

74
all docs

74
docs citations

74
times ranked

4991
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative 3D Video Microscopy of HIV Transfer Across T Cell Virological Synapses. <i>Science</i> , 2009, 323, 1743-1747.	12.6	437
2	IL-7 administration drives T cell cycle entry and expansion in HIV-1 infection. <i>Blood</i> , 2009, 113, 6304-6314.	1.4	291
3	Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 353.	7.4	236
4	Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384. <i>Clinical Infectious Diseases</i> , 2009, 48, 350-361.	5.8	202
5	Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive Subjects. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 42, 426-434.	2.1	148
6	Evidence for Calpain-Mediated Androgen Receptor Cleavage as a Mechanism for Androgen Independence. <i>Cancer Research</i> , 2007, 67, 9001-9005.	0.9	120
7	Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa-2a in HIV-1 Monoinfected Participants: A Phase II Clinical Trial. <i>Journal of Infectious Diseases</i> , 2010, 201, 1686-1696.	4.0	118
8	Molecular Characterization of Stool Microbiota in HIV-Infected Subjects by Panbacterial and Order-Level 16S Ribosomal DNA (rDNA) Quantification and Correlations With Immune Activation. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 57, 363-370.	2.1	108
9	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4A: a phase 2 randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 291-300.	9.1	100
10	Multifunctional Human Immunodeficiency Virus (HIV) Gag-Specific CD8 + T-Cell Responses in Rectal Mucosa and Peripheral Blood Mononuclear Cells during Chronic HIV Type 1 Infection. <i>Journal of Virology</i> , 2007, 81, 5460-5471.	3.4	83
11	Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, 31-38.	2.1	71
12	Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: Panel design by an empiric approach. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2008, 73A, 400-410.	1.5	65
13	Randomized pilot trial of a synbiotic dietary supplement in chronic HIV-1 infection. <i>BMC Complementary and Alternative Medicine</i> , 2012, 12, 84.	3.7	63
14	Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. <i>Aids</i> , 2013, 27, 2207-2217.	2.2	63
15	'Modeling' relationships among HIV-1 replication, immune activation and CD4+ T-cell losses using adjusted correlative analyses. <i>Aids</i> , 2000, 14, 951-958.	2.2	60
16	Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults. <i>Journal of Infectious Diseases</i> , 2016, 214, 65-72.	4.0	55
17	Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 73, 123-129.	2.1	54
18	Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164. <i>Journal of Infectious Diseases</i> , 2012, 206, 1715-1723.	4.0	50

#	ARTICLE	IF	CITATIONS
19	Comparative Cell-Mediated Immunogenicity of DNA/DNA, DNA/Adenovirus Type 5 (Ad5), or Ad5/Ad5 HIV-1 Clade B gag Vaccine Prime-Boost Regimens. <i>Journal of Infectious Diseases</i> , 2010, 201, 132-141.	4.0	47
20	Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet HIV</i> , 2021, 8, e397-e407.	4.7	42
21	Interferon-Alpha Administration Enhances CD8+ T Cell Activation in HIV Infection. <i>PLoS ONE</i> , 2012, 7, e30306.	2.5	42
22	CD4+ T-Cell Restoration After 48 Weeks in the Maraviroc Treatment-Experienced Trials MOTIVATE 1 and 2. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 54, 394-397.	2.1	37
23	Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. <i>PLoS Pathogens</i> , 2016, 12, e1005381.	4.7	37
24	HIV infection and atherosclerosis: evaluating the drivers of inflammation. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 720-728.	1.8	36
25	Physiological effects of HIV infection on human intestinal epithelial cells. <i>Aids</i> , 1994, 8, 205.	2.2	35
26	E2F1 expression in LNCaP prostate cancer cells deregulates androgen dependent growth, suppresses differentiation, and enhances apoptosis. <i>Prostate</i> , 2006, 66, 70-81.	2.3	33
27	HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. <i>Aids</i> , 2011, 25, 159-164.	2.2	32
28	Chemokine/CD4 receptor density ratios correlate with HIV replication in lymph node and peripheral blood of HIV-infected individuals. <i>Aids</i> , 2001, 15, 161-169.	2.2	30
29	A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. <i>Antiviral Research</i> , 2004, 64, 103-111.	4.1	30
30	Impact of highly active antiretroviral therapy initiation on CD4+ T-cell repopulation in duodenal and rectal mucosa. <i>Aids</i> , 2013, 27, 867-877.	2.2	29
31	Changing Patterns of Infections in Patients with AIDS: A Study of 279 Autopsies of Prison Inmates and Nonincarcerated Patients at a University Hospital in Eastern Texas, 1984-1993. <i>Clinical Infectious Diseases</i> , 1996, 23, 241-247.	5.8	28
32	Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part II: Panel performance across different instrument platforms. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 411-420.	1.5	25
33	HIV Disease Activity as a Modulator of Lipoprotein(a) and Allele-Specific Apolipoprotein(a) Levels. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 387-392.	2.4	25
34	Cytomegalovirus Glycoprotein B Groups in Human Immunodeficiency Virus-Infected Patients with Incident Retinitis. <i>Journal of Infectious Diseases</i> , 2002, 186, 114-117.	4.0	24
35	Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens. <i>Aids</i> , 2012, 26, 1625-1634.	2.2	23
36	C-Reactive Protein (CRP), Interferon Gamma-Inducible Protein 10 (IP-10), and Lipopolysaccharide (LPS) Are Associated with Risk of Tuberculosis after Initiation of Antiretroviral Therapy in Resource-Limited Settings. <i>PLoS ONE</i> , 2015, 10, e0117424.	2.5	23

#	ARTICLE	IF	CITATIONS
37	Host Gene Expression Changes Correlating With Anti-HIV-1 Effects in Human Subjects After Treatment With Peginterferon Alfa-2a. <i>Journal of Infectious Diseases</i> , 2012, 205, 1443-1447.	4.0	22
38	Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 70, 163-171.	2.1	21
39	Continued Elevation of Interleukin-18 and Interferon- γ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw118.	0.9	19
40	Entrapment of recent thymic emigrants in lymphoid tissues from HIV-infected patients. <i>Aids</i> , 2002, 16, 2119-2127.	2.2	18
41	Role of intestinal myofibroblasts in HIV-associated intestinal collagen deposition and immune reconstitution following combination antiretroviral therapy. <i>Aids</i> , 2015, 29, 877-888.	2.2	18
42	Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6372-6378.	3.2	15
43	Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial. <i>Clinical Nutrition</i> , 2019, 38, 1303-1309.	5.0	14
44	Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV monoinfection and HIV/HCV coinfection. <i>Journal of Medical Virology</i> , 2012, 84, 431-437.	5.0	13
45	Treatments for Hepatitis B. <i>Clinical Infectious Diseases</i> , 2004, 39, 1353-1362.	5.8	12
46	Replication Capacity in Relation to Immunologic and Virologic Outcomes in HIV-1-Infected Treatment-Naïve Subjects. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 50, 250-258.	2.1	12
47	Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV coinfected patients. <i>Journal of Medical Virology</i> , 2010, 82, 791-798.	5.0	12
48	Mucosal immunity in HIV infection. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 275-281.	3.1	12
49	Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 216, 813-818.	4.0	12
50	Associations of Plasma Cytokine and Microbial Translocation Biomarkers With Immune Reconstitution Inflammatory Syndrome. <i>Journal of Infectious Diseases</i> , 2017, 216, 1159-1163.	4.0	12
51	Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection. <i>Transfusion</i> , 2003, 43, 451-458.	1.6	11
52	Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection. <i>Antiviral Research</i> , 2004, 63, 123-131.	4.1	10
53	Serum Bovine Immunoglobulins Improve Inflammation and Gut Barrier Function in Persons with HIV and Enteropathy on Suppressive ART. <i>Pathogens and Immunity</i> , 2019, 4, 124.	3.1	10
54	Homeostasis of Naïve and Memory T Cell Subpopulations in Peripheral Blood and Lymphoid Tissues in the Context of Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2001, 183, 1336-1342.	4.0	9

#	ARTICLE	IF	CITATIONS
55	Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164. HIV Clinical Trials, 2014, 15, 133-139.	2.0	9
56	Lessons from maraviroc clinical trials. Expert Review of Anti-Infective Therapy, 2011, 9, 649-651.	4.4	8
57	Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. HIV Clinical Trials, 2015, 16, 72-80.	2.0	8
58	Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption. PLoS ONE, 2019, 14, e0210965.	2.5	8
59	Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo. Journal of AIDS & Clinical Research, 2015, 06, .	0.5	7
60	Peginterferon α -2a for the treatment of HIV infection. Expert Opinion on Investigational Drugs, 2016, 25, 249-257.	4.1	7
61	Hepatic Safety of Maraviroc in Patients with HIV-1 and Hepatitis C and/or B Virus: 144-Week Results from a Randomized, Placebo-Controlled Trial. Antiviral Therapy, 2017, 22, 263-269.	1.0	6
62	Delayed gastrointestinal-associated lymphoid tissue reconstitution in duodenum compared with rectum in HIV-infected patients initiating antiretroviral therapy. Aids, 2019, 33, 2289-2298.	2.2	6
63	Potential use of <sc>serum-derived</sc> bovine immunoglobulin/protein isolate for the management of <sc>COVID</sc>-19. Drug Development Research, 2021, 82, 873-879.	2.9	5
64	Cell cycle kinetic dysregulation in HIV-infected normal lymphocytes. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2005, 66A, 41-51.	1.5	4
65	Estimating cell death in G2M using bivariate BrdUrd/DNA flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2005, 66A, 32-40.	1.5	3
66	UC Davis CTSA: Coming of Age. Clinical and Translational Science, 2009, 2, 98-101.	3.1	3
67	HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. PLoS ONE, 2020, 15, e0224875.	2.5	3
68	Microsporidia and diarrhea in AIDS patients. Clinical Microbiology Newsletter, 1994, 16, 179-183.	0.7	2
69	Evaluation of oral serum-derived bovine immunoglobulins in HIV-infected patients with chronic idiopathic diarrhea. HIV Clinical Trials, 2017, 18, 205-213.	2.0	2
70	<title>Importance of high-throughput cell separation technologies for genomics/proteomics-based clinical diagnostics</title>. , 2002, , .		1
71	Women are from venus: implications for diversified sex-based preexposure prophylaxis approaches. Aids, 2021, 35, 1691-1693.	2.2	0